Sure, and I’m sure there are more examples, but take Myriad Genetics. There entire company is based on BRCA 1&2 testing. They once had the patent for these genes, but continue to be the clear leader in BRCA testing once they lost the patent.
The reason? When testing becomes a commodity, it means it’s widely used. Myriad was the original owner of the patent and therefore developed the expertise to employ this testing.
I’m thinking, and this would be ambitious, HDC could do the same with their expired patents. Although they’re no longer “exclusive” with the technology, they can market it as a “me too” product with the advantage of being the experts (as was Myriad to the BRCA genes).
You are looking at this through the 2.2 mil lens but this re-launching of HDC is viewed from the "more to come" lens. But again, I'm not arguing for this outcome, only that there is more to come than the 2.2 mil.
News 
Market Data 
Discover 
